Results 81 to 90 of about 1,821 (152)

Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study. [PDF]

Rheumatology (Oxford)
Kang EH, Shin A, Park CS, Lee EB, Lee YJ, Curhan G, Choi HK.   +6 more
europepmc   +1 more source

Human genetic evidence supports fibroblast growth factor 21 as a novel therapeutic target for gout. [PDF]

Rheumatology (Oxford)
Zhao SS, Cuthbertson DJ, Alam U.
europepmc   +1 more source

Identifying Aspirin as a Contributing Factor to Persistent Gout: A Case Report. [PDF]

Cureus
Nguyen J, Liang Y, Islam A, Kakarala V, Overturf MD.   +4 more
europepmc   +1 more source

Calcinosis Cutis Universalis: A Review of Therapeutic Strategies and Surgical Management. [PDF]

J Clin Med
Giacometti E, Martineau J, Petrou IG, Kalbermatten DF, Scampa M.   +4 more
europepmc   +1 more source

Diabetes and gout: another role for SGLT2 inhibitors? [PDF]

Ther Adv Endocrinol Metab
Bailey CJ.
europepmc   +1 more source

Superiority of Low-Dose Benzbromarone Add-On to Low-Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined-Type Hyperuricemia. [PDF]

Arthritis Care Res (Hoboken)
Xue X, Sun M, Yan F, Dalbeth N, He Y, Li X, Qi H, Chen Y, Yuan X, Li M, Ji A, Terkeltaub R, Li C.   +12 more
europepmc   +1 more source

Efficacy and safety of urate-lowering therapies in asymptomatic hyperuricaemia: a systematic review and network meta-analysis of key clinical outcomes. [PDF]

Ann Med
Yi Y, Yang J, Chen Y, Liu H, Deng Y.
europepmc   +1 more source